ReviewBlood cancer journal2026
Aberrant glycosylation in hematologic malignancies: mechanisms, immune evasion, and therapeutic targeting.
Review in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ST6GAL1 Glycoengineering Rewires Cytokine Signaling and Preserves Metabolic Fitness in CAR-T Cells Under Galectin-3-Mediated Immunosuppression.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hematologic malignancies are a group of malignant diseases originating from hematopoietic stem cells or the lymphatic system, mainly including leukemia, lymphoma, myeloma and so on. These diseases are characterized by their high heterogeneity, rapid disease progression and poor prognosis. Glycosylation is one of the most common post-translational modifications. In recent years, it has been found that abnormal glycosylation plays an important role in the genesis, development and treatment of hematologic malignancies. Aberrant glycosylation has been demonstrated to exert a significant influence on the progression of disease, impacting various biological processes including tumor cell signaling, the tumor microenvironment, cellular recognition, and immune evasion. This review synthesizes recent advances in how dysregulated glycosylation drives the biology of leukemia, lymphoma, myeloma, and other types of malignancies. Additionally, it discusses the potential value of glycosylation products that can be used as biomarkers for disease diagnosis and prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.